Certara (CERT) Stock Analysis & AI Equity Report
Certara (CERT) overview
Certara (CERT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 419m and operating profit of USD 21.0m; the year-end share price was 8.81 USD and market capitalisation was USD 1,402m. Certara is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Certara's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Certara
Certara provides biosimulation software, data solutions, and consulting services to biopharmaceutical and biotechnology companies. Its tools and scientific services support model-informed drug development, including research, preclinical work, clinical development, and commercialization. The company also helps clients collect, standardize, validate, store, and analyze scientific data and prepare regulatory documents for drug development.
Generate the Certara report
Certara is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Certara and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Certara
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.